Patents by Inventor Kensuke OHSE

Kensuke OHSE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10214584
    Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: February 26, 2019
    Assignee: ORDER-MADE MEDICAL RESEARCH INC.
    Inventors: Hiroyuki Satofuka, Kensuke Ohse, Shigeki Mukobata, Hirotada Akiyama, Masaya Ohtsu, Yoko Okabe, Yasufumi Murakami
  • Publication number: 20160333092
    Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.
    Type: Application
    Filed: January 15, 2015
    Publication date: November 17, 2016
    Applicant: ORDER-MADE MEDICAL RESEARCH INC.
    Inventors: Hiroyuki SATOFUKA, Kensuke OHSE, Shigeki MUKOBATA, Hirotada AKIYAMA, Masaya OHTSU, Yoko OKABE, Yasufumi MURAKAMI
  • Publication number: 20160009799
    Abstract: The object of the present invention is to prepare a cancer therapeutic agent by means of a novel monoclonal antibody which binds to SLC6A6 or its extracellular region and a substance which suppresses SLC6A6 expression. The present invention provides a pharmaceutical composition comprising a monoclonal antibody which recognizes native SLC6A6 or a polypeptide in the extracellular region of SLC6A6.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 14, 2016
    Applicant: ORDER-MADE MEDICAL RESEARCH INC.
    Inventors: Hiroyuki SATOFUKA, Kensuke OHSE, Shigeki MUKOBATA, Yumiko KATO, Yoko OKABE, Yasuhiro MATSUMURA, Masahiro YASUNAGA